Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients With Metastatic Urothelial Carcinoma.
Daniel P PetrylakBernhard J EiglSaby GeorgeElisabeth I HeathSebastien J HotteDavid D ChismLisle M NabellJoel PicusSusanna Y ChengLeonard J ApplemanGuru P SonpavdeAlicia K MorgansPourya PourhosseiniRuishan WuLaura StandleyRuslan CroitoruEvan Y YuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
DLTs with AGS15E were observed at 0.75, 1.00, and 1.25 mg/kg, with an RP2D of 1.00 mg/kg being determined.
Keyphrases